描述

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 亿期间 2021-2027, 以复合年增长率增长 (复合年增长率) 的 8.6% 在预测期内, 据数据和分析公司 StrategyHelix 称. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

该报告提供了该时期的最新市场规模数据 2017-2020 并预测到 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, 技术, age, analysis target, 和地区. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. 按技术, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, 和别的. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., Agilent Technologies Inc., BGI Group, Centogene AG, Eurofins Scientific SE, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics Incorporated.

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

疾病: cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases
技术: polymerase chain reaction (PCR), next-generation sequencing, microarrays, 和别的
Age: children, and adult
地区: 北美, 亚太地区, 欧洲, 和世界其他地区 (排)
Analysis target: multiple genes, whole exome, single genes, and whole genome
考虑年数: 本报告涵盖期间 2017 到 2027

利益相关者的主要好处

Get a comprehensive picture of the global rare disease diagnostics market
根据当地数据和分析确定区域战略和战略重点
精准定位增长领域和投资趋势
Understand what the future of the global rare disease diagnostics market looks like
确定竞争格局和机会之窗

目录

1. 市场定义
2. 研究方法论
3. 市场数据 & 外表
3.1 市场价值
3.2 市场价值预测
4. Rare Disease Diagnostics Market by Disease
4.1 Cardiovascular
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 Hematology
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 Polymerase Chain Reaction (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 其他的
6. Rare Disease Diagnostics Market by Age
6.1 孩子们
6.2 成人
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 北美
8.2 亚太地区
8.3 欧洲
8.4 世界其他地区 (排)
9. 公司简介
9.1 3billion Inc.
9.2 Agilent Technologies Inc.
9.3 BGI Group
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 Illumina Inc.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 PerkinElmer, 公司.
9.10 Quest Diagnostics Incorporated
10. 附录
10.1 关于StrategyHelix
10.2 免责声明